|
|
市场分析报告
|
Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029
... granted accelerated approval to Mirati Therapeutics’ Adagrasib (Krazati) which is a RAS GTPase family ...
Global KRAS Inhibitors Market & Clinical Trials Forecast 2028
... consists of several potential candidates including Adagrasib, JQ443, GDC-6036, BI 1823911, ... 1084, and others. Among them, Adagrasib is one of the most advanced ... with Sanofi to evaluate the combination of adagrasib with Sanofi’s investigational SHP2 ...
Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030
... of the RAS GTPase family, Krazati (adagrasib), developed by Mirati Therapeutics, a wholly owned ... drug application (sNDA) for Krazati (adagrasib) in combination with cetuximab for the ...
Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. "Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025" Report Highlights: KRAS Inhibitors Market Opportunity: > USD 1 Billion ...
KRAS Market by Target Indication (Acute Myeloid Leukemia, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Phelan-McDermid Syndrome, and Skin Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy and Combination Therapy), and Route of Administration (Intravenous, Intramuscular, Intradermal, Intraocular, Intraperitoneal, Oral, and Subcutaneous), Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2031
The NRAS, HRAS and KRAS market is expected to reach USD 73 million in 2021 and anticipated to grow at a CAGR of 53.6% during the forecast period 2021-2031 In 2020, an estimated 10 million reported fatalities were attributed to cancer, standing as a ...
Blood Collection Tubes for Liquid Biopsy Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, Intracellular RNA Tubes, and Others), Material (Plastic and Glass), Application [In-vitro Diagnostics (IVD), and Research], End User (Genetic Diagnostic Labs, Research and Development Centers, Conventional Diagnostic Centers, and Others),and Geography
... may benefit from the KRAZATI (adagrasib) treatment. Such approvals from the ...
Global KRAS Inhibitor Market Research Report 2024, Forecast to 2032
... of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation ...
Global KRAS Inhibitor Market Growth 2024-2030
... of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation ...
Non-Small Cell Lung Cancer Market Assessment, By Type [Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Others], By Treatment Type [Chemotherapy, Targeted Therapy, Immunotherapy], By Drug Class [Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/PD-L1 Inhibitor], By Distribution Channel [Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Pharmacy], By Region, Opportunities and Forecast, 2016-2030F
... , provided accelerated approval to Mirati's Krazati (adagrasib), offering a targeted treatment for adult ...
Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), By End-use (Hospitals, Specialty Clinics), By Region (North America, Europe), And Segment Forecasts, 2025 - 2030
... contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non ...
Global KRAS Inhibitor Market Research Report 2025(Status and Outlook)
... of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation ...
Global Pancreatic Cancer Treatment Market - 2025-2033
Overview The global pancreatic cancer treatment market size reached US$ 5.09 billion in 2024 and is expected to reach US$ 9.65 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033. Pancreatic Cancer is the seventh leading cause ...
Novel Drug Delivery Systems in Cancer Therapy Market Forecasts to 2030 – Global Analysis By Drug Type (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Therapy Drugs, Hormonal Therapy Drugs, Gene Therapy Drugs, and Other Drug Types), Delivery Method, Drug Release Type, Technology, Application, End User and By Geography
... FDA accelerated approval for KRAZATI (adagrasib) in combination with cetuximab, a targeted treatment ...
Global Cancer Gene Therapy Market - 2025 -2033
... , The FDA has approved a combination of adagrasib and cetuximab for KRAS G12C ...
|
|
|
|
